drugset / Trial / NCT04158349
Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is a prospective, multi-center, open-label phase I trial designed to determine the maximun tolerated dose of IP oxaliplatin when given in combination with mFOLFIRI.
Timeline
- Start
- 2021-03-22
- Primary completion
- 2021-05-14
- Completion
- 2021-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 95 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 105 mg/m2 | Other |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |